Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Jennifer R. Brown(Dana-Farber Cancer Institute), Mazyar Shadman(University of Washington), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Lugui Qiu(Chinese Academy of Medical Sciences & Peking Union Medical College), Aileen Cohen(Düsseldorf University Hospital), Tommi Salmi(Düsseldorf University Hospital), Andrzej Mital(Gdańsk Medical University), Habte Yimer(Texas Oncology), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Peter Ganly(European Bioinformatics Institute), Constantine S. Tam(The Alfred Hospital), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Anders Österborg(Karolinska University Hospital), Keshu Zhou(Zhengzhou University), Jiřı́ Mayer(Masaryk University), Amanda Gillespie-Twardy(Düsseldorf University Hospital), Sebastian Grosicki(Medical University of Silesia), Megan-Der-Yu Wang(Düsseldorf University Hospital), Kenneth Wu(Düsseldorf University Hospital), Martin Šimkovič(Charles University), Tadeusz Robak(Medical University of Lodz), Barbara Eichhorst(University of Cologne), Jessica Li(Universidad San Carlos), Lina Fu(Düsseldorf University Hospital), Maciej Kaźmierczak(Silesian University of Technology), Robert Weinkove(Malaghan Institute of Medical Research), Wojciech Jurczak(Jagiellonian University), Susan O’Brien(University of California, Irvine)
Cited by 453
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k